As of 2025-12-31, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 477.44 mil USD. SAGE's TTM EBITDA according to its financial statements is -294.68 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.6x - 15.3x | 14.0x |
| Forward P/E multiples | 21.9x - 43.4x | 32.6x |
| Fair Price | (101.72) - (70.74) | (108.29) |
| Upside | -1271.9% - -915.0% | -1347.6% |
| Date | EV/EBITDA |